Literature DB >> 8576282

Paclitaxel in the management of ovarian cancer: what we know and what we have yet to learn.

M Markman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8576282     DOI： 10.1007/bf01226263

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN： 0171-5216            Impact factor:   4.553


× No keyword cloud information.
  10 in total

1.  Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms.

Authors:  W P McGuire; E K Rowinsky; N B Rosenshein; F C Grumbine; D S Ettinger; D K Armstrong; R C Donehower
Journal:  Ann Intern Med       Date:  1989-08-15       Impact factor: 25.391

2.  Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma.

Authors:  A I Einzig; P H Wiernik; J Sasloff; C D Runowicz; G L Goldberg
Journal:  J Clin Oncol       Date:  1992-11       Impact factor: 44.544

3.  Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines.

Authors:  N M Lopes; E G Adams; T W Pitts; B K Bhuyan
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

4.  Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer.

Authors:  E C Kohn; G Sarosy; A Bicher; C Link; M Christian; S M Steinberg; M Rothenberg; D O Adamo; P Davis; F P Ognibene
Journal:  J Natl Cancer Inst       Date:  1994-01-05       Impact factor: 13.506

5.  Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.

Authors:  J T Thigpen; J A Blessing; H Ball; S J Hummel; R J Barrett
Journal:  J Clin Oncol       Date:  1994-09       Impact factor: 44.544

6.  Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion.

Authors:  W H Wilson; S L Berg; G Bryant; R E Wittes; S Bates; A Fojo; S M Steinberg; B R Goldspiel; J Herdt; J O'Shaughnessy
Journal:  J Clin Oncol       Date:  1994-08       Impact factor: 44.544

7.  European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion.

Authors:  E A Eisenhauer; W W ten Bokkel Huinink; K D Swenerton; L Gianni; J Myles; M E van der Burg; I Kerr; J B Vermorken; K Buser; N Colombo
Journal:  J Clin Oncol       Date:  1994-12       Impact factor: 44.544

8.  Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol.

Authors:  E K Rowinsky; R C Donehower; R J Jones; R W Tucker
Journal:  Cancer Res       Date:  1988-07-15       Impact factor: 12.701

Review 9.  Paclitaxel (taxol)

Authors:  E K Rowinsky; R C Donehower
Journal:  N Engl J Med       Date:  1995-04-13       Impact factor: 91.245

10.  Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103.

Authors:  E L Trimble; J D Adams; D Vena; M J Hawkins; M A Friedman; J S Fisherman; M C Christian; R Canetta; N Onetto; R Hayn
Journal:  J Clin Oncol       Date:  1993-12       Impact factor: 44.544
  10 in total
  1 in total

Review 1.  Paclitaxel. An update of its use in the treatment of metastatic breast cancer and ovarian and other gynaecological cancers.

Authors:  L R Wiseman; C M Spencer
Journal:  Drugs Aging       Date:  1998-04       Impact factor: 3.923
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.